EUVIMEDEUVIMED entdecken
Crossref

Target identification for natural products inhibiting oncogenic ERK/AKT signaling in malignant melanoma

M Karpouchtsi, L Dürr, M Dobrzyński, S Radetzki, T Hell, R E van Diest, M Smieško, M Hamburger, J P von Kries, O Pertz, R Teufel, E Garo

Planta Medica · 01.03.2026 · 92 (03) · 417-418

DOI: 10.1055/s-0045-1815452 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Planta Medica, erschienen am 01.03.2026. Verfasst von M Karpouchtsi und 11 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Malignant melanoma is the deadliest type of skin cancer driven by high mutation rates arising in both MAPK/ERK and PI3K/AKT signaling pathways. While targeted therapies show initial promise, drug resistance develops quickly, leaving patients with limited options. Novel treatments are therefore urgently needed. As part of a broader drug discovery effort, we conducted two screening campaigns: one using our in-house library of 2,576 crude extracts, and another one leveraging large libraries of over 25,000 pure compounds from both natural and synthetic origin. Using a specifically developed high-content screening (HCS) assay that reports on downstream ERK and AKT activity, we identified 42 active compounds with IC 50 values below 20 μM. The current challenge focuses on identifying the molecular targets of the most promising hits – an essential step toward understanding their mode of action and therapeutic potential. However, target deconvolution remains a significant challenge, particularly for phenotypic assays. To address this, we developed a complementary strategy to explore compound-target interactions that includes computational methods, thermostability-based binding assays and selective kinase activity assays. Key kinases of the ERK-AKT network were produced using different cloning techniques and heterologous expression systems for testing in these assays. Challenges encountered in target identification and first insights into potential targets will be presented. Ultimately, we aim to advance our newly discovered inhibitors into lead compounds for future drug development [ 1 ] [ 2 ]. Publication History Article published online: 05 March 2026 © 2026. Thieme. All rights reserved. Georg Thieme Verlag KG Oswald-Hesse-Straße 50, 70469 Stuttgart, Germany

Zitieren

APA

Karpouchtsi, M., Dürr, L., Dobrzyński, M., Radetzki, S., Hell, T., Diest, R. E. V., Smieško, M., Hamburger, M., Kries, J. P. V., Pertz, O., Teufel, R., & Garo, E. (2026). Target identification for natural products inhibiting oncogenic ERK/AKT signaling in malignant melanoma. Planta Medica, 92(03), 417-418. https://doi.org/10.1055/s-0045-1815452

Vancouver

Karpouchtsi M, Dürr L, Dobrzyński M, Radetzki S, Hell T, Diest REV, et al. Target identification for natural products inhibiting oncogenic ERK/AKT signaling in malignant melanoma. Planta Medica. 2026;92(03):417-418. doi:10.1055/s-0045-1815452

BibTeX
@article{Karpouchtsi2026,
  author = {Karpouchtsi, M and Dürr, L and Dobrzyński, M and Radetzki, S and Hell, T and Diest, R E van and Smieško, M and Hamburger, M and Kries, J P von and Pertz, O and Teufel, R and Garo, E},
  title = {Target identification for natural products inhibiting oncogenic ERK/AKT signaling in malignant melanoma},
  journal = {Planta Medica},
  year = {2026},
  volume = {92},
  number = {03},
  pages = {417--418},
  doi = {10.1055/s-0045-1815452}
}
Kostenlos starten →